Cardama Alfonso Quintas 4

What Happened

• Alfonso Cardama, Chief Medical Officer of Foghorn Therapeutics (FHTX), was granted a derivative award (option) to acquire 300,000 shares on January 30, 2026. The option strike/price reported is $5.71 per share, giving a notional value of $1,713,000 on the grant date. This is a grant (an award of options), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-30; Filing date: 2026-02-02 (Form 4) — filed within the SEC’s reporting window (timely).
• Instrument: derivative award (option) to acquire 300,000 shares; reported price/strike $5.71; reported value $1,713,000.
• Shares owned after the transaction: not specified in this filing.
• Footnote (F1): The option vests 25% of the underlying shares on January 30, 2027, then vests at 6.25% of the underlying shares on the first day of each calendar quarter thereafter (standard multi-year vesting).
• No immediate sale or cashless exercise reported.

Context

• This filing documents an option grant (a common form of executive compensation). It gives Cardama the right to buy up to 300,000 shares at $5.71 per share as the award vests; it does not represent an immediate purchase of shares or a sale. Grants are compensation-related and do not by themselves indicate the insider has bought shares on the open market or sold holdings.